These findings demonstrate that Calanquinone A exerts potent antitumor effects in glioblastoma by targeting the STAT3/c-Myc and STAT3/MMP9 signaling axes, supporting its potential as a natural STAT3-targeting agent for GBM therapy. This evidence concerns the gene MYC and glioblastoma.